Dapagliflozin - Chong Kun Dang Pharmaceutical
Alternative Names: CKD-380Latest Information Update: 15 Jan 2022
At a glance
- Originator CKD Pharmaceuticals
- Class Anti-ischaemics; Antihyperglycaemics; Antivirals; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules; Urologics
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in South Korea (PO, Tablet)
- 14 Aug 2018 Chemical structure information added
- 02 Aug 2018 Chong Kun Dang Pharmaceuticals completes enrolment in the phase I trial for Type-2 diabetes mellitus (In volunteers) in South Korea (PO) before August 2018 (NCT03601910)